ATRI atrioncorp.com: Company Value to Revenue

Official company branding of Atrion (ATRI)

Atrion Corporation (ATRI) relies on stable demand in cardiac surgery and ophthalmology, maintaining high margins on consumables while remaining debt-free. However, disruptions in metal supply chains and geopolitical logistical challenges are increasing production costs and hindering exports. The EV/Sales ratio demonstrates a period of consolidation, and captures a new level, signaling a decrease in volatility ahead of a potential impulse.

atrioncorp.com (ATRI): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

ATRI (Atrion Corporation Inc.): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental company valuation:ATRI - Atrion
Manufactured products of Atrion Corp

The market value of Atrion Corporation (ATRI) relative to the scale of its operations allows for an assessment of the premium investors are willing to pay for stable income from the sale of specialized medical equipment. By analyzing the EV/Sales valuation multiple, which combines market capitalization and net debt relative to annual revenue, one can determine the asset's degree of overbought status and the risk of a correction should demand for cardiovascular and ophthalmological instruments slow down.

Direct competitors

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio InfuSystem Holdings, Inc.|Enterprise Value-to-Revenue Multiple Utah Medical Products UTMD|EV/Sales Multiple KRMD|Total Company Value-to-Revenue Ratio Nyxoah, S.A.|Microbot Medical Inc - Company Value to Revenue|Total Company Value-to-Revenue Ratio Pro-Dex Inc. (PDEX)|Zentek - EV/Sales Multiple|Elutia (ELUT) - Company Value to Revenue|Milestone Scientific Inc (MLSS) - Enterprise Value-to-Revenue Ratio|NXGL - Total Company Value-to-Revenue Ratio|Company Value to Revenue RVP|Harvard Bioscience, Inc. (HBIO) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple FEMY|EV/Sales Multiple Meihua Medical Technologies (MHUA)|EV/Sales Multiple POAI (Predictive Oncology)|CJMB - Company Value to Revenue|NeuroMetrix Corporation - EV/Sales Multiple